Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study
Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m 2 , paclitaxel 155 mg/m 2 (both day 1) and capecitabine 665 mg/m 2 twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2008-01-01
|
| Series: | Clinical Medicine Insights: Oncology |
| Online Access: | https://doi.org/10.4137/CMO.S1027 |
| _version_ | 1819111310610137088 |
|---|---|
| author | Z. Einbeigi M.D. D. Bergström T. Hatschek M. Malmberg |
| author_facet | Z. Einbeigi M.D. D. Bergström T. Hatschek M. Malmberg |
| author_sort | Z. Einbeigi M.D. |
| collection | DOAJ |
| description | Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m 2 , paclitaxel 155 mg/m 2 (both day 1) and capecitabine 665 mg/m 2 twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively. |
| first_indexed | 2024-12-22T03:55:35Z |
| format | Article |
| id | doaj.art-9dddf0c22e0b41858e6e7277e7fe3fef |
| institution | Directory Open Access Journal |
| issn | 1179-5549 |
| language | English |
| last_indexed | 2024-12-22T03:55:35Z |
| publishDate | 2008-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Clinical Medicine Insights: Oncology |
| spelling | doaj.art-9dddf0c22e0b41858e6e7277e7fe3fef2022-12-21T18:39:53ZengSAGE PublishingClinical Medicine Insights: Oncology1179-55492008-01-01210.4137/CMO.S1027Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility StudyZ. Einbeigi M.D.0D. Bergström1T. Hatschek2M. Malmberg3Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden.Roche AB, Stockholm, Sweden.Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden.Department of Oncology, Helsingborg Hospital, Helsingborg, Sweden.Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m 2 , paclitaxel 155 mg/m 2 (both day 1) and capecitabine 665 mg/m 2 twice daily (days 1-14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.https://doi.org/10.4137/CMO.S1027 |
| spellingShingle | Z. Einbeigi M.D. D. Bergström T. Hatschek M. Malmberg Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study Clinical Medicine Insights: Oncology |
| title | Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study |
| title_full | Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study |
| title_fullStr | Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study |
| title_full_unstemmed | Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study |
| title_short | Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: A Pilot Phase I/II Feasibility Study |
| title_sort | paclitaxel epirubicin and capecitabine tex as first line treatment for metastatic breast cancer a pilot phase i ii feasibility study |
| url | https://doi.org/10.4137/CMO.S1027 |
| work_keys_str_mv | AT zeinbeigimd paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy AT dbergstrom paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy AT thatschek paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy AT mmalmberg paclitaxelepirubicinandcapecitabinetexasfirstlinetreatmentformetastaticbreastcancerapilotphaseiiifeasibilitystudy |